METHOD DEVELOPMENT AND VALIDATION OF CLOPIDOGREL DRUG IN THE DRUG SUBSTANCES AND DOSAGE FORM BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

  • Rishabh K Dagariya Institute of Pharmacy, Shri Jagadish Prasad Jhabarmal Tibrewala University, Jhunjhunu, Rajasthan, India
  • Rakesh K Jat Institute of Pharmacy, Shri Jagadish Prasad Jhabarmal Tibrewala University, Jhunjhunu, Rajasthan, India

Abstract

The present work describes a validated reverse phase high performance liquid chromatographic method for estimation of Clopidogrel in the drug substances and dosage form. The quantification was carried out using Ultron ES OVM (150*4.6) mm, 5µm and mobile phase comprised of Buffer, Acetonitrile and in proportion of 70:30 %v/v. The flow rate was 1.0 ml/min and the eluent was monitored at 220 nm. The selected chromatographic conditions were found to effectively quantitate Clopidogrel at retention time of about 3.8 min. Linearity were found to be in the range of 11-75 μg/ml. The percentage recoveries of all the drugs were found to be 99.3-101.1%. The proposed method was found to be fast, specific, accurate, precise, and reproducible and can be used for estimation of the Clopidogrel drugs.

Keywords: Clopidogrel, Reversed-phase HPLC.

Downloads

Download data is not yet available.

Author Biographies

Rishabh K Dagariya, Institute of Pharmacy, Shri Jagadish Prasad Jhabarmal Tibrewala University, Jhunjhunu, Rajasthan, India

Institute of Pharmacy, Shri Jagadish Prasad Jhabarmal Tibrewala University, Jhunjhunu, Rajasthan, India

Rakesh K Jat, Institute of Pharmacy, Shri Jagadish Prasad Jhabarmal Tibrewala University, Jhunjhunu, Rajasthan, India

Institute of Pharmacy, Shri Jagadish Prasad Jhabarmal Tibrewala University, Jhunjhunu, Rajasthan, India

References

1. Ahuja S, Dong MW, (2005), Handbook of Pharmaceutical Analysis by HPLC, Elsevier/Academic Press
2. Saravanan V., Revathi R., Meera N. method development and validation for the simultaneous estimation of lycopene and ubidecarenone by RP-HPLC in combined pharmaceutical dosage form. Journal of Drug Delivery and Therapeutics, 2016; 6(5):46-51. doi:10.22270/jddt.v6i5.1295
3. Kazakevich YK, LoBrutto R, (2007), HPLC for Pharmaceutical Scientists, Wiley.
4. Bhowmick M., Bhowmick P., Sengodan T., Thangavel S. Development and validation of bioanalytical RP HPLC method for the estimation of metoprolol tartrate in rabbit plasma after transdermal and oral administration: application in pharmacokinetic studies. Journal of Drug Delivery and Therapeutics, 2015; 5(4):43-53. doi:10.22270/jddt.v5i4.1118
5. Lloyd R. Snyder and John W. Dolan (2008) A recent book provides a comprehensive treatment of the theory of high-performance gradient chromatography.
6. Snyder LR, Kirkland JJ, Dolan JW, (2009)Introduction to Modern Liquid Chromatography,
7. Dong MW, (2009) Modern HPLC for practicing scientists. Wiley
8. Savi P, Zachayus JL, Delesque-Touchard N et al. "The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers & partitions them out of lipid rafts". Proceedings of the National Academy of Sciences of the USA 2006; 103(29):11069-11074.
9. Pereillo JM, Maftouh M, Andrieu A, Uzabiaga MF, Fedeli O, Savi P, Pascal M, Herbert JM, Maffrand JP, Picard C. "Structure and stereochemistry of the active metabolite of clopidogrel". Drug Metab. Dispos. 2002; 30(11):1288–95.
10. Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006.
11. Michael D Randall; Karen E Neil (2004). Disease management. 2nd ed. London: Pharmaceutical Press. 159.
12. Chan FK, Ching JY, Hung LC, et al. "Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding". N. Engl. J. Med. 2005; 352(3):238–44.
13. John Wiley & Sons, New York, (1997) LC Method Development
14. Neue UD, (1997) HPLC Columns: Theory, Technology, and Practice, Wiley-VCH, New York
Statistics
46 Views | 94 Downloads
How to Cite
Dagariya, R., & Jat, R. (2018). METHOD DEVELOPMENT AND VALIDATION OF CLOPIDOGREL DRUG IN THE DRUG SUBSTANCES AND DOSAGE FORM BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY. Journal of Drug Delivery and Therapeutics, 8(4), 176-178. https://doi.org/10.22270/jddt.v8i4.1756